Stoke Therapeutics (NASDAQ:STOK) Shares Up 6.9% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price was up 6.9% during mid-day trading on Friday . The company traded as high as $32.35 and last traded at $32.5070. 378,671 shares changed hands during trading, a decline of 46% from the average daily volume of 700,505 shares. The stock had previously closed at $30.40.

Analysts Set New Price Targets

STOK has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a report on Monday, May 11th. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Needham & Company LLC upped their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Wedbush lifted their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Stock Performance

The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -11.31 and a beta of 1.17. The company has a fifty day simple moving average of $31.58 and a 200 day simple moving average of $32.36.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The business had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics in the fourth quarter worth about $26,000. KBC Group NV purchased a new stake in shares of Stoke Therapeutics in the first quarter worth about $36,000. Harbour Investments Inc. boosted its holdings in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new position in Stoke Therapeutics during the third quarter worth about $41,000. Finally, BNP Paribas Financial Markets increased its position in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.